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The nCounter PanCancer Immune Profiling Panel is a
unique 770-plex gene expression panel to measure the
human immune response in both solid and liquid cancer
types. The panel measures many features of the immune
response to facilitate rapid development of clinical action-
able gene expression profiles in the context of cancer
immunotherapy. The assay is run on the nCounter Analysis
System (Nanostring Technologies, Inc.), an automated
system which received 510(k) clearance from the FDA for
use with the Prosigna Breast Cancer Prognostic Gene
Signature Assay [1]. The nCounter Analysis System is based
on a novel digital color-coded barcode technology which
allows for direct multiplexed measurement of gene expres-
sion from low amount of mRNA (25 to 300 ng) without
need for amplification [2]. The technology uses molecular
“barcodes” and single molecule imaging to detect and count
(completely digital) hundreds of unique transcripts in a
single reaction with high precision and sensitivity (<1 copy
per cell). Each color-coded optical barcode is attached to a
single target-specific hybridization probe corresponding to
a gene of interest. Mixed together with controls, they form
multiplexed “CodeSets” which are provided as ready to use
reagents (Fig. 1). Currently three “CodeSets” are available as
ready to use reagents for oncology investigations: a) the
PanCancer Pathways - a panel of 700 essential genes repre-
senting major cancer pathways including key driver genes -
b) the PanCancer progression - a panel of 770 genes from 4
major biologic processes that contribute to increased tumor
growth and invasiveness including angiogenesis, epithelial
to mesenchymal transition and extra-matrix remodeling
and metastasis and c) the PanCancer Immune profiling
panel (described in more details below). Multiple CodeSets
can be run on the same samples thus proving integrated
information about both tumor and host immune response.
At a very high level, the assay includes three main
steps:
1. Hybridization: unique pairs of a “capture” and a
“reporter” probe are provided for each gene of
interest, allowing up to 800 genes to be multiplexed,
and their mRNA transcript levels measured, in a
single experiment, for each sample. The “reporter”
probe carries the signal, and the “capture” probe
allows the complex to be immobilized for data
collection.
2. Purification and immobilization: after hybridization,
samples are transferred to the nCounter Prep
Station where excess probes are removed and probe/
target complexes are bound, immobilized, and
aligned on the nCounter Cartridge.
3. Counting and Analysis: sample cartridges are placed
in the nCounter Digital Analyzer for data collection.
The time from sample lysates to data results is two days
and because the process is highly automated the hands-on
time (and therefore room for human errors) is limited
(25 min per 12 samples). Measurements are performed
using the commercially available nCounter Analysis In-
strumentation at the site of sample collection or through
working with any of the multiple Contract Research Orga-
nizations offering NanoString services.
For application of this technology to immune-oncology
the nCounter PanCancer Immune Profiling Panel provides
a highly multiplexed gene expression panel designed to
quantitate 770 genes that fall into four functional categories
(Fig. 1):
1. Identifying 24 different infiltrating immune cell
types, such as those in a peripheral blood
mononuclear cells (PBMC) population or infiltrating
into a tumor.
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2. Assessing immunological function and response to
immunotherapy, such as immune checkpoint
regulation.
3. Identifying tumor-specific antigens, such as cancer-
testis (CT) antigens.
4. Housekeeping genes that facilitate sample-to-sample
normalization.
Type of data obtained/readout
Barcodes are counted and tabulated for each target by the
nCounter Digital Analyzer. The data readouts are either the
composite of the individual expression profile of cells
within that population; or detailed, single-cell level ex-
pression, which may represent biologically relevant small
percentage (5-10 %) of the entire population of the cells.
The instrument analysis software automatically performs
QC, normalization, data analysis and creates multi-page
reports with the options of performing advanced analyses
including pathway applications.
Limitations of the approach
 The data are not spatially resolved, hence, it
represents the average of a few 1000’s of cells
 The data are targeted discovery (as contrasted with
pure discovery), and measure only the 770 genes
predefined in the panel. It is possible to add 30
completely custom genes to the 770-plex panel
(total of 800-plex)
 While it is possible to resolve alternate splice
transcripts and expressed gene-fusions, the panel
does not measure single-nucleotide polymorphisms
(SNPs).
Advantages of the approach
 Multiplex hundreds of gene targets in a single
reaction
 High sensitivity (<1 copy per cell)
 Fully-automated system
 No enzymes or amplification required to perform
assay, ideally suited for FFPE samples and cell lysates
 Multiplex 800 regions from as little as 25-300 ng of
total RNA
 Completely digital detection (all quantitation is by
direct single-molecule counting)
 Automated analysis software
Types of samples needed and special issues pertaining to
samples
The nCounter PanCancer Immune profiling panel is fully
compatible with clinically relevant sample types such as
fresh-frozen (FF) tissue, formalin-fixed paraffin-embedded
(FFPE) tumor sections, isolated immune cell populations
each observed barcode is one read
measured nucleic acid
PanCancer Immune Profi ling Panel
Immune response categories:
• B cell functions
• T cell functions

































Fig. 1 (left) Molecular barcoding. NanoString Molecular barcodes consist of 6 fluorescent “spots” that can be any one of 4 colors each [hence
arranged in 4^6 combinations (4096), of which 800 have been commercialized], each specific color combination represents a single mRNA
species to be measured. The mRNA from the sample of interest (red) hybridizes to the complementary nucleic-acid attached to an optical
barcode pattern representing that specific gene. While the hybridization event occurs in solution, the final digital counting of the barcode-
nucleic-acid component is performed, single molecule at-a-time, stretched-out on the surface of the nCounter cartridge (spot-pattern on
black background). (right) Schematic representation of the PanCancer Immune Profiling Panel. This 770-plex assay contains: 109 genes to cell
surface markers capable of quantitating 24 different tumor infiltrating immune cell types and populations, 30 genes for commonly studied CT
Antigens, over 500 genes for measuring immune response with a special emphasis on checkpoint regulation/signaling, 40 PanCancer Reference
Genes. The panel can be further “customized” (by individual researchers) with the addition of up to 30 genes with our Panel-Plus feature.
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such as PBMC and cell lysates. For very low input samples
(even down to single-cell work, such at CTCs), a multi-
plexed target enrichment amplification protocol is available.
Level of evidence
There have been bout over 800 peer-reviewed publications
using the nCounter Analysis System. The instrument,
reagents and software have received 510(k) clearance from
the FDA for use with the Prosigna Breast Cancer Prognos-
tic Gene Signature Assay [1]. There is a growing body of
literature available demonstrating the use of the nCounter
analysis system using much of the same content as in the
nCounter PanCancer Immune Profiling Panel in immuno-
oncology setting [3].
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